

2011

Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration

Siobhan Sutcliffe

Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St. Louis

Remington L. Nevin

Bayne-Jones Army Community Hospital

Ratna Pakpahan

Washington University School of Medicine in St. Louis

Debra J. Elliott

Johns Hopkins University

Stephen R. Cole

University of North Carolina at Chapel Hill

Follow this and additional works at: https://digitalcommons.wustl.edu/canpre_pubs

See next page for additional authors



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Sutcliffe, Siobhan; Nevin, Remington L.; Pakpahan, Ratna; Elliott, Debra J.; Cole, Stephen R.; De Marzo, Angelo M.; Gaydos, Charlotte A.; Isaacs, William B.; Nelson, William G.; Sokoll, Lori J.; Zenilman, Johnathan M.; Cersovsky, Steven B.; and Platz, Elizabeth A., "Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration" (2011). *Cancer Prevention Faculty Publications*. Paper 1.

https://digitalcommons.wustl.edu/canpre_pubs/1

This Article is brought to you for free and open access by the Division of Public Health Sciences Faculty Publications at Digital Commons@Becker. It has been accepted for inclusion in Cancer Prevention Faculty Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Siobhan Sutcliffe, Remington L. Nevin, Ratna Pakpahan, Debra J. Elliott, Stephen R. Cole, Angelo M. De Marzo, Charlotte A. Gaydos, William B. Isaacs, William G. Nelson, Lori J. Sokoll, Johnathan M. Zenilman, Steven B. Cersovsky, and Elizabeth A. Platz

**PROSTATE INVOLVEMENT DURING SEXUALLY TRANSMITTED INFECTIONS
AS MEASURED BY PROSTATE SPECIFIC ANTIGEN CONCENTRATION**

Siobhan Sutcliffe¹, Remington L. Nevin², Ratna Pakpahan³, Debra J. Elliott⁴,
Stephen R. Cole⁵, Angelo M. De Marzo⁶, Charlotte A. Gaydos⁷,
William B. Isaacs⁸, William G. Nelson⁹, Lori J. Sokoll¹⁰, Jonathan M. Zenilman¹¹,
Steven B. Cersovsky¹², Elizabeth A. Platz¹³

¹Division of Public Health Sciences and the Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine; 660 S. Euclid Ave., Box 8100, Rm. 5026, St. Louis, MO 63110, USA.

²Department of Preventive Medicine, Bayne-Jones Army Community Hospital; 1585 3rd St., Folk Port, LA 71459, USA.

³Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine; 660 S. Euclid Ave., Box 8100, Rm. 5019, St. Louis, MO 63110, USA.

⁴Department of Pathology, Johns Hopkins Medical Institutions; 600 N. Wolfe St., Meyer B-194, Baltimore, MD 21287, USA.

⁵Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill; McGavran-Greenberg Hall, Campus Box 7435, Chapel Hill, NC 27599, USA.

⁶Departments of Pathology and Oncology, James Buchanan Brady Urological Institute, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions; CRB-1 Rm. 151, 1650 Orleans St., Baltimore, MD 21205, USA.

⁷Division of Infectious Diseases, Department of Medicine, Johns Hopkins Medical Institutions; 855 North Wolfe St., 530 Rangos Building, Baltimore, MD 21205, USA.

⁸James Buchanan Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions; 115 Marburg Bldg., 600 N. Wolfe St., Baltimore, MD 21205, USA.

⁹Departments of Oncology, Pathology, and Pharmacology, James Buchanan Brady Urological Institute, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions; 401 North Broadway St., The Weinberg Building, Suite 1100, Baltimore, MD 21231, USA.

¹⁰Department of Pathology, James Buchanan Brady Urological Institute, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions; 600 N. Wolfe St., Meyer B-125, Baltimore, MD 21287, USA.

¹¹Division of Infectious Diseases, Department of Medicine, Johns Hopkins Medical Institutions; 4940 Eastern Ave., Baltimore, MD 21224, USA.

¹²U.S. Army Institute of Public Health, U.S. Army Public Health Command (Provisional); 5158 Blackhawk Road, Aberdeen Proving Ground, MD 21010, USA.

¹³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the James Buchanan Brady Urological Institute and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions; 615 N. Wolfe St., Room E6132 Baltimore, MD 21205, USA.

Running title: Prostate involvement in sexually transmitted infections

Corresponding author: Siobhan Sutcliffe, Division of Public Health Sciences and the Alvin J.

Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, 660

S. Euclid Ave., Box 8100, Rm. 5026, St. Louis, MO 63110, USA. E-mail:

sutcliffes@wudosis.wustl.edu.

Abstract: 99

Text: 1,600

ABSTRACT

Background: We investigated prostate involvement during sexually transmitted infections by measuring serum prostate specific antigen (PSA) as a marker of prostate infection, inflammation, and/or cell damage in young, male U.S. military members.

Methods: We measured PSA before and during infection for 299 chlamydia, 112 gonorrhea, and 59 non-chlamydial, non-gonococcal urethritis (NCNGU) cases, and 256 controls.

Results: Chlamydia and gonorrhea, but not NCNGU, cases were more likely to have a large rise ($\geq 40\%$) in PSA than controls (33.6%, 19.1%, and 8.2% versus 8.8%, $p < 0.0001$, 0.021, and 0.92, respectively).

Conclusion: Chlamydia and gonorrhea may infect the prostate of some infected men.

Key words: Sexually transmitted infections; chlamydia; gonorrhea; non-chlamydial, non-gonococcal urethritis; prostate specific antigen; prostate cancer.

INTRODUCTION

Despite ongoing interest in the role of exudative sexually transmitted infections (STIs; i.e., those that cause an inflammatory discharge) in prostate carcinogenesis (Sutcliffe, 2010), few studies have examined the likelihood of prostate involvement during infection, particularly in the current antibiotic era (Sutcliffe & Platz, 2007). We previously investigated this question by measuring serum prostate specific antigen (PSA) as a marker of prostate infection, inflammation, and/or cell damage in a small study of young, African-American STI patients (Sutcliffe *et al*, 2006). We used PSA as a marker because it rises in men with acute bacterial prostatitis and asymptomatic histologic prostate inflammation (Sindhvani & Wilson, 2005). In our previous study, we found that men with exudative STIs were more likely to have a large rise ($\geq 40\%$) in PSA during infection than controls, suggesting that prostate infection occurred in some infected men. To investigate the reproducibility of these findings and determine which STIs predict PSA elevation, we have now conducted a considerably larger study among U.S. military members with stored serum in the Department of Defense serum repository (DoDSR).

METHODS

Study population and design

The DoDSR contains serum remaining from human immunodeficiency virus type 1 (HIV-1) screening during pre-induction, at routine periodic intervals (every 2-5 years), before and after major overseas deployments, for clinical indications, and as part of standard clinical STI work-up. Specimens are linked to demographic information, service-related activity, and reportable (e.g., genital, chlamydial infection; gonorrhea; and non-chlamydial, non-gonococcal

urethritis (NCNGU)) and non-reportable medical diagnoses (Rubertone & Brundage, 2002; Silverberg *et al*, 2003).

Men eligible for the present study were those who were <25 years of age as of 1995; HIV-1-negative; on continuous active duty from 1995-2006; and had several archived specimens in the DoDSR (n=75,387). We defined STI cases as men with a laboratory-confirmed diagnosis of chlamydia (ICD-9-CM code 099.41), gonorrhea (098), or NCNGU (099.40) in 2001-2003. Diagnoses were confirmed according to military guidelines; NCNGU required specific exclusion of chlamydia and gonorrhea (July, 1998). We defined controls as men with no STI or infectious mononucleosis diagnoses in their medical record up to 2006. Exclusion of mononucleosis diagnoses was needed for a separate investigation. Controls were frequency-matched to the entire case group by race.

For each case, we selected two specimens from the DoDSR, one collected ± 7 days of the case diagnosis (acute), and the first specimen collected >3 weeks before their acute specimen to account for the maximum typical incubation period of chlamydia and gonorrhea ((Hook & Handsfield, 2008; Stamm, 2008), pre-acute, range: 22 days-4 years before diagnosis). If a case had ≥ 2 diagnoses, only one was selected. Diagnoses without a specimen collected ± 7 days were excluded. These criteria resulted in a sample size of 299 chlamydia, 112 gonorrhea, and 59 NCNGU cases. Two specimens were also selected for each control, one collected from 2001-2003 (“acute”) and the first specimen collected >3 weeks before their acute specimen (“pre-acute”). If ≥ 2 “acute” specimens were available, one was randomly selected. Of the 68,584 eligible controls, we selected 256 based on power considerations and available resources.

This study was approved by the Walter Reed Army Institute of Research and Johns Hopkins. All data/specimens were anonymized before release from the DoDSR.

PSA measurement

As participants were younger than the age range for routine prostate cancer screening, PSA was not available in their medical records. Therefore, we measured total PSA for all participants using the Access Hybritech assay (Beckman Coulter, Brea, CA). Specimens from the same individual were tested adjacent to one another in random within-person order. We determined assay reproducibility by testing 25 blinded quality control pairs from the DoDSR (coefficient of variation=12.4% and 6.9% after excluding one discrepant pair). Total PSA has been found to be relatively stable for 2-20 years at -20°C (Ulmert *et al*, 2006; Woodrum & York, 1998), close to the storage temperature in the DoDSR (-30°C).

Statistical analysis

We initially explored PSA change between the pre-acute and acute specimens by comparing mean pre-acute and acute PSA for cases and controls. Values were adjusted for race to account for frequency-matching. We further explored PSA change by comparing race-adjusted categories of absolute and relative percent change. As in our previous analysis (Sutcliffe *et al*, 2006), case and control distributions diverged at a 40-49% PSA rise; therefore, we used a $\geq 40\%$ change to define a large rise.

RESULTS

We identified 299 cases of chlamydia, 112 of gonorrhea, and 59 of NCNGU, and selected 256 controls for comparison. Compared to controls, cases were slightly younger; gonorrhea cases were more likely to be African-American; and all cases were more likely to be unmarried, enlisted, and to have had their blood drawn for clinical indications (Table 1). Cases also had a

greater number of blood draws, and a correspondingly shorter time between draws, particularly between their pre-acute and acute specimens.

In general, STI cases had a higher mean pre-acute PSA than controls ($p=0.0023$, Table 2). Comparing pre-acute and acute specimens, chlamydia cases had a significantly greater mean change in PSA between specimens than controls, and were more likely to have a large rise in PSA at the time of their acute specimen, as defined by both absolute and relative change. For gonorrhea, although cases did not have a significantly greater mean change in PSA than controls, they were more likely to have both a large absolute and relative rise. The magnitude of this difference was, however, smaller than for chlamydia ($p=0.0005$). NCNGU cases were no more likely to have a large PSA rise than controls. No changes were observed after adjustment for age, calendar year of the pre-acute specimen, time between specimens, and pre-acute PSA. Only one of the four cases with recorded prostate symptoms (ICD-9-CM code 601) at the time of their STI diagnosis had a large PSA rise.

As men were not necessarily tested for STIs at the time of their pre-acute specimen, we repeated the analyses restricted to men with ≥ 1 year between their pre-acute and acute specimens to remove men more likely to have been infected with their subsequently diagnosed acute STI at the time of their pre-acute specimen; in general, similar results were obtained. We also investigated the influence of additional diagnosed or undiagnosed STIs on the results by excluding: 1) men with additional infectious or genitourinary diagnoses immediately before their pre-acute specimen or between specimens; 2) cases with clinical or other suspicion of HIV/STIs as their reason for blood draw for their pre-acute specimen, and controls with these reasons for either specimen; 3) men with small breaks (<60 days) in their active duty status or deployed

between specimens; and 4) higher rank officers who may have greater access to non-military health care. All sensitivity analyses yielded similar results as the main analyses (data not shown).

DISCUSSION

In this large study of U.S. military members, men with exudative STIs were more likely to have a large PSA rise during infection than controls, similar to findings from our previous smaller study of STI patients (Sutcliffe *et al*, 2006). This rise was observed for chlamydia and gonorrhea, but not for NCNGU. Although cases were also more likely to have higher pre-acute PSA, this difference should not have influenced inferences for PSA change because similar findings were observed for absolute and relative change, only the latter of which varies depending on the pre-acute value.

While all STIs had the potential for prostate involvement (Sutcliffe & Platz, 2007; Sutcliffe & Platz, 2008), chlamydia cases were most likely to have a large PSA rise, followed by gonorrhea cases, whereas NCNGU cases were no more likely to have a rise than controls. One possible reason for these differences may be likelihood of symptoms as a possible marker of duration of infection. We previously hypothesized that men with asymptomatic infections/non-specific symptoms might be more likely to have prostate infection because of their likely lesser awareness of their STI and consequent delay seeking treatment. This delay might provide pathogens with greater opportunity to ascend to and infect the prostate, which we believe is a likely necessary first step for prostate carcinogenesis (Sutcliffe *et al*, 2006). This hypothesis is consistent with differences in the likelihood of symptoms for each STI. Approximately half of chlamydial infections are asymptomatic in men (Zimmerman *et al*, 1990), a large proportion of which are ultimately diagnosed in the military because of routine female screening, contact

tracing, and self-referral for risky behaviors; 1-49% of gonorrheal infections present without symptoms (Pedersen & Harrah, 1970; Turner *et al*, 2002); and a likely even smaller proportion of diagnosed NCNGU infections present without symptoms because NCNGU is typically only investigated in men with urethral symptoms. An alternative explanation for null NCNGU findings, but not for differences between chlamydia and gonorrhea, is that some NCNGU cases did not have an infectious etiology.

Although we used PSA as a marker of prostate infection/inflammation/cell damage, PSA may also possibly rise as a result of a more generalized response to infection at other non-prostate sites (e.g., urethra), recent ejaculation (within one day), or digital rectal examination (DRE) (Tchetgen & Oesterling, 1997). We believe these possibilities are less likely because of null results for NCNGU, an STI defined by urethral inflammation; unchanged results after adjustment for sexual activity in our previous study (Sutcliffe *et al*, 2006); and the extreme rarity with which DREs are performed during routine STI work-up, especially in the military.

In summary, young men with chlamydia and gonorrhea were more likely to have a large PSA rise during infection than controls. Future studies should investigate the specificity of this rise to prostate infection, as well as the long-term effects of infections on PSA and, by possible extension, the prostate environment.

ACKNOWLEDGMENTS

This study was funded by the Patrick C. Walsh Prostate Cancer Research Fund. We thank Dr. Angelia A. Eick and Zheng Hu at the Armed Forces Health Surveillance Center for help with participant selection, and Dr. Catherine G. Sutcliffe for help preparing serum specimens for testing and coordinating PSA testing.

Information in this manuscript was presented at the Annual American Urological Association Meeting in Chicago, IL, in April, 2009 (abstract 175).

REFERENCES

- (July, 1998) *Army Medical Surveillance Activity. Tri-service reportable events guidelines and case definitions.*
- Hook EWI, Handsfield HH (2008) Gonococcal infections in the adult. In *Sexually transmitted diseases, 4th ed.*, Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH (eds), pp 627-46. New York: The McGraw-Hill Companies, Inc
- Pedersen AH, Harrah WD (1970) Followup of male and female contacts of patients with gonorrhoea. *Public Health Rep* **85**: 997-1000
- Rubertone MV, Brundage JF (2002) The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. *Am J Public Health* **92**: 1900-4
- Silverberg MJ, Brundage JF, Rubertone MV (2003) Timing and completeness of routine testing for antibodies to human immunodeficiency virus type 1 among active duty members of the U.S. Armed Forces. *Mil Med* **168**: 160-4
- Sindhwani P, Wilson CM (2005) Prostatitis and serum prostate-specific antigen. *Curr Urol Rep* **6**: 307-12
- Stamm WE (2008) *Chlamydia trachomatis* infections of the adult. In *Sexually transmitted diseases, 4th ed.*, Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH (eds), pp 575-94. New York: The McGraw-Hill Companies, Inc
- Sutcliffe S (2010) Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. *Future Oncol* **6**: 1289-311
- Sutcliffe S, Platz EA (2007) Inflammation in the etiology of prostate cancer: an epidemiologic perspective. *Urol Oncol* **25**: 242-9
- Sutcliffe S, Platz EA (2008) Inflammation and prostate cancer: a focus on infections. *Curr Urol Rep* **9**: 243-9
- Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, Nelson WG, De Marzo AM, Cole SR, Isaacs WB, Platz EA (2006) Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. *J Urol* **175**: 1937-42
- Tchetgen MB, Oesterling JE (1997) The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. *Urol Clin North Am* **24**: 283-291

Turner CF, Rogers SM, Miller HG, Miller WC, Gribble JN, Chromy JR, Leone PA, Cooley PC, Quinn TC, Zenilman JM (2002) Untreated gonococcal and chlamydial infection in a probability sample of adults. *JAMA* **287**: 726-33

Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H (2006) Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. *Clin Chem* **52**: 235-9

Woodrum D, York L (1998) Two-year stability of free and total PSA in frozen serum samples. *Urology* **52**: 247-51

Zimmerman HL, Potterat JJ, Dukes RL, Muth JB, Zimmerman HP, Fogle JS, Pratts CI (1990) Epidemiologic differences between chlamydia and gonorrhea. *Am J Public Health* **80**: 1338-42

Table 1: Demographic characteristics^a of 470 young, male sexually transmitted infection (STI) cases and 256 controls, U.S. military 2001-2003

	Controls (n=256)	Chlamydia cases (n=299)	Gonorrhea cases (n=112)	NCNGU cases (n=59)	p-value ^b
Mean Age (years) ^c	29.9	29.2	29.0	29.1	<0.0001 (<0.0001)
Race/ethnicity (%): ^d					
African-American	55.1	54.2	79.5	52.5	
Caucasian-American	36.3	36.1	16.1	35.6	0.0007 (0.27)
Other	8.6	9.7	4.4	11.9	
Marital status (%): ^c					
Married	79.3	60.7	63.5	73.4	
Other	20.7	39.3	36.5	26.6	<0.0001 (<0.0001)
Military grade (%): ^c					
Enlisted	91.1	96.2	97.3	99.0	
Officer	8.9	3.8	2.7	1.0	0.011 (0.0012)
Reason for blood draw (%): ^c					
Routine ^e	69.6	22.3	25.0	17.6	
Clinically indicated/Part of an STI visit ^f	1.9	34.2	48.7	70.4	<0.0001 (<0.0001)
Other/unknown	28.5	43.5	26.4	12.0	
Mean number of blood draws for HIV-1 testing from Jan. 1, 1995 to Dec. 31, 2006	9.9	12.0	11.3	13.4	<0.0001 (<0.0001)
Mean time between pre-acute and acute specimens (months)	16.8	11.9	12.0	10.7	<0.0001 (<0.0001)

NCNGU = non-chlamydial, non-gonococcal urethritis

^a Values for cases and controls were calculated by linear regression adjusting for race (African-American, non-African-American), except for values for the race variable.

^b P-values were calculated by linear regression for continuous or binary variables, and by generalized logit regression for categorical variables. All models were adjusted for race (African-American, non-African-American). P-values reflect a test of independence across all groups. Values in parentheses compare all cases to controls.

^c At the time of blood draw of the acute specimen.

^d Cases were frequency-matched to controls by race/ethnicity.

- ^e Indicates blood drawn for routine and pre- and post-deployment human immunodeficiency virus type 1 (HIV-1) tests, as well as HIV-1 tests performed as part of specialized physical examinations (e.g., for flight school).
- ^f Indicates blood drawn for self or clinical suspicion of HIV-1 or STIs, as well as from hospitalized patients or those visiting emergency rooms for certain clinical indications. Blood draws are coded as “clinically indicated/part of an STI visit” irrespective of the results of HIV-1 or STI testing.

Table 2: Pre-acute and acute serum total prostate specific antigen (PSA) concentration for 470 young, male sexually transmitted infection cases and 256 controls, U.S. military 2001-2003

PSA (ng/mL)	Controls (n=256)		Chlamydia cases (n=299)		p-value ^a	Gonorrhea cases (n=112)		p-value ^a	NCNGU cases (n=59)		p-value ^a
	Pre-acute	Acute	Pre-acute	Acute		Pre-acute	Acute		Pre-acute	Acute	
Geometric mean ^b	0.55	0.56	0.62	0.82	<0.0001	0.66	0.70	0.47	0.63	0.64	0.84
Mean ^b	0.64	0.65	0.86	1.11	0.0078	0.80	0.93	0.32	0.70	0.82	0.33
Range ^c	0.38-0.76	0.38-0.80	0.43-0.87	0.52-1.33		0.44-0.98	0.44-1.04		0.48-0.82	0.46-0.86	
Distribution of absolute change in serum total PSA (%) ^b											
≤0.00 ng/mL	52.1		36.2			45.1			48.8		
0.01-0.09 ng/mL	24.7		19.8			31.1			30.6		
0.10-0.19 ng/mL	15.1		9.0			4.0			10.5		
0.20-0.29 ng/mL	2.8		7.4		<0.0001	6.1		0.0023	3.5		0.57
0.30-0.39 ng/mL	2.1		5.5			1.5			1.9		
0.40-0.49 ng/mL	1.6		2.4			1.5			0.1		
≥0.50 ng/mL	1.6		19.7			10.6			4.6		
Distribution of relative percent change in serum total PSA (%) ^b											
≤0%	52.1		36.2			45.1			48.8		
0.1-9%	11.7		12.7			21.7			12.3		
10-19%	12.8		7.9			10.0			18.5		
20-29%	10.1		5.6		<0.0001	1.9		0.0044	11.8		0.38
30-39%	4.5		3.9			2.2			0.3		
40-49%	1.8		5.6			3.8			3.3		
≥50%	7.0		28.0			15.3			5.0		
Large relative rise in PSA (%) ^b											
≥40%	8.8		33.6		<0.0001	19.1		0.021	8.2		0.92

NCNGU = non-chlamydial, non-gonococcal urethritis

^a P-values were calculated by linear regression with robust variance estimation for continuous variables, logistic regression for categorical variables and linear regression for binary variables. All models were adjusted for race (African-American, non-African-American).

^b Values were calculated by linear regression adjusting for race (African-American, non-African-American).

^c Not adjusted for race.